| Post marketing adverse event reporting lists the following as
frequent events (occurring in at least 1/100 patients exposed to
glatiramer acetate): Amenorrhoea (absence or stopping of period);
menorrhagia (abnormally heavy bleeding).
Additionally, suspicious papanicolaou smears (pap smear) and vaginal
haemorrhage were reported as frequent post marketing events.
It is unknown whether these events are related to exposure to glatiramer
acetate (Copaxone ®).
|
